Publications: Dr Paolo Gallipoli

Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M et al. ( 2024 ) . Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation . Blood

Sánchez-Lanzas R, Barclay J, Hardas A, Kalampalika F, Jiménez-Pompa A, Gallipoli P, Ganuza M ( 2024 ) . A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones . Leukemia1 - 13 .

Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M et al. ( 2024 ) . Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation . Blood vol. 144 , ( Supplement 1 )

James SC, Atkinson S, Burt R, Lo Celso C, Gallipoli P ( 2024 ) . Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML . Blood vol. 144 , ( Supplement 1 ) 4152 - 4152 .

Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R et al. ( 2024 ) . Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy . Blood Advances vol. 8 , ( 21 ) 5590 - 5597 .

Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J et al. ( 2024 ) . Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy . Leukemia vol. 38 , ( 11 ) 2443 - 2455 .

Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P et al. ( 2024 ) . Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia . EBioMedicine vol. 108 ,

Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H et al. ( 2024 ) . Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS . Blood Neoplasia vol. 1 , ( 3 )

Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J et al. ( 2024 ) . Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation . Leukemia vol. 38 , ( 11 ) 2395 - 2409 .

Rodriguez Cutillas P, Borek WE, Christopher JA, Nobre LV, Campbell A, Kelsall J, Pedicona F, Nawaz N et al. ( 2024 ) . Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML) . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 6525 - 6525 .

Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ et al. ( 2024 ) . Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy . British Journal of Haematology vol. 205 , ( 3 ) 947 - 955 .

Lawson H, Holt-Martyn JP, Dembitz V, Kabayama Y, Wang LM, Bellani A, Atwal S, Saffoon N et al. ( 2024 ) . The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia . Nature Cancer vol. 5 , ( 6 ) 916 - 937 .

Dembitz V, Durko J, Campos J, James SC, Lawson H, Kranc KR, Gallipoli P ( 2024 ) . Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts . HemaSphere vol. 8 , ( 1 )

Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif A-L et al. ( 2024 ) . Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy . Blood vol. 143 , ( 4 ) 336 - 341 .

Milojkovic D, Blijlevens N, Kwong Y-L, Zaidi U, Castagnetti F, Gallipoli P, Miggiano MC, Westerweel PE et al. ( 2023 ) . Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP) . Blood vol. 142 , ( Supplement 1 )

Dokal A, Borek WE, Nobre L, Pedicona SF, Wrench B, Gallipoli P, Arruda A, Campbell AE et al. ( 2023 ) . S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT‐POSITIVE ACUTE MYELOID LEUKAEMIA . HemaSphere vol. 7 , ( Suppl )

Philippe C, Mian S, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D et al. ( 2023 ) . O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS . Leukemia Research vol. 128 ,

Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS et al. ( 2023 ) . Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death . Nature Communications vol. 14 , ( 1 )

Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M et al. ( 2023 ) . The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia . Bone Marrow Transplantation vol. 58 , ( 7 ) 826 - 828 .

Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I et al. ( 2023 ) . C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia . Cancer Discovery vol. 13 , ( 7 ) 1720 - 1747 .

Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D et al. ( 2023 ) . Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia . Science Translational Medicine vol. 15 , ( 685 ) eabn5135 - eabn5135 .

Dembitz V, Lawson H, Philippe C, Burt RJ, James S, Magee ASM, Woodley K, Durko J et al. ( 2022 ) . Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia . Blood vol. 140 , ( Supplement 1 ) 3058 - 3060 .

Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M et al. ( 2022 ) . Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy . Blood vol. 140 , ( Supplement 1 ) 2033 - 2035 .

Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, Khan A, Byrne J et al. ( 2022 ) . Real-World Experience of Asciminib: Factors Associated with Response . Blood vol. 140 , ( Supplement 1 ) 6796 - 6797 .

Lawson H, Holt-Martyn J, Dembitz V, Durko J, Kabayama Y, Wang L, Van De Lagemaat L, Dubusse L et al. ( 2022 ) . Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML . Blood vol. 140 , ( Supplement 1 ) 8731 - 8732 .

Gallipoli P ( 2022 ) . AML gets upSET when its dietary needs are unMet . Blood vol. 140 , ( 19 ) 2003 - 2004 .

Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA et al. ( 2022 ) . A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies . Clinical Cancer Research vol. 29 , ( 4 ) 711 - 722 .

Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Copland M et al. ( 2022 ) . P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE . HemaSphere vol. 6 , 601 - 602 .

Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM, O’Brien S ( 2022 ) . The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia . British Journal of Haematology vol. 196 , ( 6 ) e55 - e57 .

Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T et al. ( 2021 ) . Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service . Blood vol. 138 , ( Supplement 1 )

Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J et al. ( 2021 ) . Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service . Blood vol. 138 , ( Supplement 1 )

Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Tzelepis K, Philippe C, Rattigan K, Asby R et al. ( 2021 ) . Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia . Blood vol. 138 , ( Supplement 1 )

Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A et al. ( 2021 ) . Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia . Blood vol. 138 , ( Supplement 1 )

Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D et al. ( 2021 ) . Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression . Nature Genetics vol. 53 , ( 10 ) 1443 - 1455 .

Dembitz V, Gallipoli P ( 2021 ) . The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia . Frontiers in Oncology vol. 11 ,

Hughes CFM, Gallipoli P, Agarwal R ( 2021 ) . Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome . Pathology

Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH et al. ( 2020 ) . Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy . Cell Metabolism vol. 32 , ( 5 ) 829 - 843.e9 .

Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P, Deliliers GL ( 2020 ) . Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study . Clinical Lymphoma Myeloma & Leukemia vol. 20 , ( 8 ) e461 - e467 .

Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P et al. ( 2020 ) . A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease . Leukemia vol. 34 , ( 7 ) 1775 - 1786 .

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P et al. ( 2019 ) . Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies . Blood vol. 134 , ( 24 ) 2195 - 2208 .

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ et al. ( 2019 ) . Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML) . Blood vol. 134 , ( Supplement_1 )

Yun H, Vohra S, Mupo A, Giotopoulos G, Sasca D, Horton SJ, Agrawal-Singh S, Meduri E et al. ( 2019 ) . Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction . Blood . vol. 134 ,

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L et al. ( 2019 ) . Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML . Journal of Experimental Medicine vol. 216 , ( 4 ) 966 - 981 .

Gallipoli P, Huntly BJP ( 2019 ) . Histone modifiers are oxygen sensors . Science vol. 363 , ( 6432 ) 1148 - 1149 .

Gallipoli P, Huntly BJP ( 2019 ) . Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML . Clinical Cancer Research vol. 25 , ( 2 ) 460 - 462 .

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu W-H, Gozdecka M, Metzakopian E et al. ( 2018 ) . SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 . Nature Communications vol. 9 , ( 1 )

Dickinson M, Kamdar M, Huntly BJP, De Larrea CF, Cordoba R, Mateos M-V, Alegre A, Kim W-S et al. ( 2018 ) . A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL) . Blood . vol. 132 ,

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L ( 2018 ) . Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation . Journal of Thrombosis and Thrombolysis vol. 47 , ( 1 ) 155 - 156 .

Gallipoli P ( 2018 ) . JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients . Leukemia Research vol. 75 , 71 - 72 .

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L et al. ( 2018 ) . Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition . Blood vol. 131 , ( 15 ) 1639 - 1653 .

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L ( 2017 ) . High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation . Journal of Thrombosis and Thrombolysis vol. 45 , ( 1 ) 106 - 113 .

Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A et al. ( 2017 ) . Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors . Nature Cell Biology . vol. 19 , 1093 - 1104 .

Gallipoli P, Huntly BJP ( 2017 ) . Novel epigenetic therapies in hematological malignancies: Current status and beyond . Seminars in Cancer Biology vol. 51 , 198 - 210 .

Gallipoli P, Costa ASH, Vohra S, Castro C, Griffin J, Frezza C, Huntly B ( 2017 ) . Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia . The Lancet . vol. 389 ,

Gallipoli P, Costa AS, Tzelepis K, Giotopoulos G, Vohra S, Vassiliou G, Frezza C, Huntly B ( 2017 ) . METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA . HAEMATOLOGICA . vol. 102 , 18 - 19 .

Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG et al. ( 2016 ) . CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression . Blood

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V et al. ( 2016 ) . A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia . Cell Reports vol. 17 , ( 4 ) 1193 - 1205 .

Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P et al. ( 2016 ) . Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition . Cancer Discovery vol. 6 , ( 11 ) 1248 - 1257 .

Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA, Castelli R ( 2016 ) . Laboratory and clinical risk assessment to treat myelodysplatic syndromes . Clinical Chemistry and Laboratory Medicine vol. 54 , ( 9 ) 1411 - 1426 .

Castelli R, Gallipoli P, Gidaro A, Maddalena W, Arquati M, Deliliers GL ( 2015 ) . Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma . Blood . vol. 126 ,

Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA, Deliliers GL ( 2015 ) . Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma . Anti-Cancer Drugs vol. 26 , ( 10 ) 1078 - 1082 .

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan W-I et al. ( 2015 ) . A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression . Journal of Experimental Medicine vol. 212 , ( 10 ) 1551 - 1569 .

Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL, Girolami MA ( 2015 ) . Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia . Systems Genetics , Cambridge University Press (CUP)

Gallipoli P, Giotopoulos G, Huntly BJP ( 2015 ) . Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia . Therapeutic Advances in Hematology vol. 6 , ( 3 ) 103 - 119 .

Giotopoulos G, Chan W-I, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E et al. ( 2015 ) . The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia . Oncogene vol. 35 , ( 3 ) 279 - 289 .

Castelli R, Pantaleo G, Gallipoli P, Arquati M, Wu MA, Deliliers GL, Cicardi M ( 2015 ) . SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA . HAEMATOLOGICA . vol. 100 , 740 - 740 .

Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R et al. ( 2014 ) . JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo . Blood vol. 124 , ( 9 ) 1492 - 1501 .

Colombo R, Gallipoli P, Castelli R ( 2014 ) . Thrombosis and Hemostatic Abnormalities in Hematological Malignancies . Clinical Lymphoma Myeloma & Leukemia vol. 14 , ( 6 ) 441 - 450 .

Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P, Pantaleo G ( 2014 ) . Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function . Annals of Hematology vol. 93 , ( 9 ) 1523 - 1529 .

Castelli R, Deliliers GL, Colombo R, Gallipoli P, Pantaleo G ( 2014 ) . BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK/INTERMEDIATE 1 MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE AND BRAIN FUNCTION . HAEMATOLOGICA . vol. 99 , 616 - 616 .

Scott MT, Korfi K, Gallipoli P, Saffrey P, Jorgensen H, Cruz M, Hamilton A, Sinclair A et al. ( 2013 ) . Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor . Blood . vol. 122 ,

Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P et al. ( 2013 ) . The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML) . Blood vol. 122 , ( 21 )

Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG et al. ( 2013 ) . Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation . Blood vol. 122 , ( 19 ) 3335 - 3339 .

Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L et al. ( 2013 ) . Safety and efficacy of pulsed imatinib with or without G‐CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow‐up . British Journal of Haematology vol. 163 , ( 5 ) 674 - 676 .

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H et al. ( 2013 ) . Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex . Journal of the National Cancer Institute vol. 105 , ( 6 ) 405 - 423 .

McIlwaine L, Parker A, Sandilands G, Gallipoli P, Leach M ( 2013 ) . Neutrophil‐specific granule deficiency . British Journal of Haematology vol. 160 , ( 6 ) 735 - 735 .

Jiang X, Chen M, Gallipoli P, Lai D, Ringrose A, Turhan A, Eaves C, Holyoake T ( 2012 ) . 1009 Targeting Chronic Myeloid Leukemia Stem/progenitor Cells by Effective Inhibition of a Novel AHI-1-BCR-ABL-JAK2 Interaction Complex . European Journal of Cancer . vol. 48 ,

Shah M, Gallipoli P, Lyons J, Holyoake T, Jørgensen H ( 2012 ) . Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro . Blood Cells Molecules and Diseases vol. 48 , ( 3 ) 199 - 201 .

Gallipoli P, Jorgensen H, Holyoake T ( 2012 ) . Modulation of TGF-β1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells . BRITISH JOURNAL OF HAEMATOLOGY . vol. 157 , 55 - 56 .

Gallipoli P, Abraham SA, Holyoake TL ( 2011 ) . Hurdles Toward a Cure for CML: The CML Stem Cell . Hematology/Oncology Clinics of North America vol. 25 , ( 5 ) 951 - 966 .

Gallipoli P, Shepherd P, Irvine D, Drummond M, Holyoake T ( 2011 ) . Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study . British Journal of Haematology vol. 155 , ( 1 ) 128 - 130 .

Chen M, Gallipoli P, DeGeer D, Sloma I, Chan M, Lai D, Jorgensen H, Forrest D et al. ( 2011 ) . TARGETING A NOVEL AHI-1-BCR-ABL-JAK2 INTERACTION COMPLEX BY COMBINATION TREATMENT WITH ABL AND JAK2 INHIBITORS IS EFFECTIVE AGAINST CML PATIENTS'S LEUKEMIC STEM/PROGENITOR CELLS IN VITRO AND IN VIVO . EXPERIMENTAL HEMATOLOGY . vol. 39 , S18 - S18 .

DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H et al. ( 2010 ) . Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells . Blood vol. 116 , ( 21 )

Gallipoli P, Shepherd P, Mitchell L, Drummond M, Holyoake T ( 2010 ) . RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOME IN AN IMATINIB TREATED CML POPULATION FROM WEST OF SCOTLAND AND LOTHIAN . HAEMATOLOGICA . vol. 95 , 342 - 342 .

O'Mahony O, McKay P, Gallipoli P, Jackson R ( 2010 ) . A Review of Lymphoma in Non-transplant Patients on Immunosuppressive Therapy . JOURNAL OF PATHOLOGY . vol. 222 , S26 - S26 .

DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H et al. ( 2010 ) . Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells . BLOOD . vol. 116 , 1393 - 1394 .

Gallipoli P, Shepherd P, Eynaud P, Hughes M, Laird J, Rhodes S, Sefcick A, Stark A et al. ( 2010 ) . Imatinib efficacy and tolerability in a 'real world' CML population study: Results from a West of Scotland and Lothian retrospective survey . BRITISH JOURNAL OF HAEMATOLOGY . vol. 149 , 82 - 82 .

Leitch C, Shah M, Gallipoli P, Zhou P, Yule M, Holyoake TL, Jorgensen HG ( 2010 ) . JAK2 is a relevant target in chronic myeloid leukaemia . BRITISH JOURNAL OF HAEMATOLOGY . vol. 149 , 77 - 77 .

Gallipoli P, Shepherd P, Mitchell L, Drummond M, Holyoake T ( 2010 ) . RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOME IN AN IMATINIB TREATED CML POPULATION FROM WEST OF SCOTLAND AND LOTHIAN . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 95 , 342 - 342 .

Hamilton A, Gallipoli P, Nicholson E, Holyoake TL ( 2009 ) . Targeted therapy in haematological malignancies . The Journal of Pathology vol. 220 , ( 4 ) 404 - 418 .

Gallipoli P, Clark A, Leach M ( 2009 ) . The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia . American Journal of Hematology vol. 84 , ( 11 ) 750 - 753 .

Fyfe AJ, Gallipoli P ( 2009 ) . Multiple splenic calcifications . British Journal of Haematology vol. 144 , ( 6 ) 808 - 808 .

Gallipoli P, Drummond M, Leach M ( 2009 ) . Hemophagocytosis and relapsed peripheral T‐cell lymphoma . European Journal Of Haematology vol. 82 , ( 3 ) 246 - 246 .

Gallipoli P, Drummond M ( 2009 ) . Pseudotumour cerebri as a manageable side effect of prolonged all‐trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia . European Journal Of Haematology vol. 82 , ( 3 ) 242 - 243 .

Gallipoli P, Tang A, Leach M ( 2008 ) . Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia . British Journal of Haematology vol. 145 , ( 3 ) 270 - 270 .

Gallipoli P, McKay P, Jackson B, Gangopadhyay M, Leach M ( 2008 ) . EXPERIENCE OF EXTRANODAL NK/T CELL LYMPHOMAS IN THE WEST OF SCOTLAND . HAEMATOLOGICA . vol. 93 , 546 - 546 .

Gallipoli P, McKay P, Jackson B, Gangopadhyay M, Leach M ( 2008 ) . EXPERIENCE OF EXTRANODAL NK/T CELL LYMPHOMAS IN THE WEST OF SCOTLAND . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 93 , 546 - 546 .

Gallipoli P, Leach M ( 2007 ) . Gingival infiltration in acute monoblastic leukaemia . British Dental Journal vol. 203 , ( 9 ) 507 - 509 .

Gallipoli P, Jones B, McQuaker IG, Parker AN ( 2007 ) . Hickman line removal is succesfull in treating most of the septic episodes secondary to rhodoturula fungaemia in immunocompromised haemato-oncology patients . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 92 , 227 - 228 .

Gallipoli P, Robertson M, Tait RC ( 2007 ) . Off-label use of rFVIIa and its clinical effectiveness: Results from a Scottish national audit . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 92 , 31 - 32 .

Gallipoli P, Robertson M, Tait RC ( 2007 ) . Off-label use of rFVIIa and its clinical effectiveness: results from a Scottish national audit . BRITISH JOURNAL OF HAEMATOLOGY . vol. 137 , 85 - 85 .

Gallipoli P, Jones B, McQuaker IG, Parker A ( 2007 ) . Risk factors, management and consequences of rhodoturula infections in immunocompromised haematology patients . BRITISH JOURNAL OF HAEMATOLOGY . vol. 137 , 77 - 77 .

Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F, Pasanisi F ( 2005 ) . Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire . Nutrition Metabolism and Cardiovascular Diseases vol. 16 , ( 3 ) 168 - 173 .

Gallipoli P ( 2002 ) . Glasgow: a very interesting place . The BMJ vol. 324 , ( Suppl S2 )

Gallipoli P ( 2002 ) . Medical education: Britain versus Italy . The BMJ vol. 324 , ( Suppl S2 )

Clark JA, Deutch AY, Gallipoli PZ, Amara SG ( 1992 ) . Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter . Neuron vol. 9 , ( 2 ) 337 - 348 .